Dietary Supplement Glucosamine Linked to Faster Dementia Progression in New Study

Kolkata, West Bengal — June 13, 2026

A widely used over-the-counter supplement taken by millions of adults for joint stiffness may have an unintended and troubling side effect on brain health. Frequent consumption of glucosamine is associated with a 25% higher likelihood of progressing from mild cognitive impairment to full-blown dementia, according to a significant study published June 9 in Nature Metabolism. Conducted by neuroscientists at the University of Florida (UF), the research also revealed a 25% increase in mortality risk among individuals already diagnosed with Alzheimer’s disease and related dementias, raising urgent new questions about the safety of this ubiquitous dietary supplement for vulnerable populations.

Key Findings from Nearly 60,000 Patients

To understand the real-world impact of the supplement, researchers conducted a massive retrospective analysis of deidentified medical records from 59,496 individuals. These patients experienced varying levels of cognitive decline between 2012 and 2024 at UF Health facilities.

The data tracking revealed that approximately 8% of the total cohort—including 1,896 dementia patients and 2,750 individuals with mild cognitive impairment (MCI)—regularly reported taking glucosamine.

After using statistical models to control for age, sex, and other demographic variables, the researchers identified two stark trends:

• Accelerated Cognitive Decline: Patients with mild cognitive impairment who regularly took glucosamine were 25% more likely to progress to a formal dementia diagnosis compared to non-users.

• Increased Mortality Risk: For patients with established Alzheimer’s disease and related dementias (ADRD), habitual glucosamine use was linked to a 25% higher likelihood of death within the twelve-year study timeframe.

Notably, the study found no increased mortality impact for the group experiencing mild cognitive impairment alone. This distinction suggests that the supplement’s potentially harmful effects are highly dependent on biological context, becoming far more pronounced once the brain has already transitioned into a diseased state.

The Biological Mechanism: Overloading the Brain with Sugar

The research team went beyond statistical tracking to investigate why a joint supplement might damage the brain. By evaluating genetically modified mice and human brain tissue, they uncovered a specific biological pathway called hyperglycosylation.

Glycosylation is a normal, healthy process where cells attach sugar molecules to proteins. Think of it as a shipping label: proteins require these sugar tags added in a precise manner to fold correctly, travel to their designated location, and perform their biological jobs.

However, in the presence of Alzheimer’s disease, this system apparently becomes hyperactive. By introducing extra glucosamine—a naturally occurring sugar-related molecule capable of crossing the protective blood-brain barrier—the researchers inadvertently supercharged this system.

“What we found in Alzheimer’s is that this sugar-tagging system appears to be overactive,” explained Matt Gentry, Ph.D., chair of UF’s Department of Biochemistry and Molecular Biology and co-author of the study. “The Alzheimer’s brain is adding too many of these sugar structures, and this seems to contribute to the disease rather than protect against it.”

In animal models, mice receiving glucosamine exhibited rapid degradation in social memory, losing the baseline ability to recognize and remember other individuals. When the researchers introduced a chemical compound to suppress this excess sugar-attachment process, the mice’s memory functions improved.

To validate these findings in humans, the team analyzed brain specimens from the UF Neuromedicine Brain and Tissue Bank. They confirmed that Alzheimer’s disease brain specimens possessed significantly higher levels of these irregular sugar attachments than normal, cognitively healthy controls.

Expert Commentary: Correlation vs. Causation

Despite the alarming numbers, leading independent experts urge the public to view these findings with cautious interest rather than panic. Because this was an observational analysis of medical records rather than a controlled clinical trial, it cannot definitively prove that glucosamine causes dementia to worsen.

“The electronic health record data are quite intriguing,” Gentry noted, maintaining scientific objectivity. “While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention.”

Senior author Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation at UF’s McKnight Brain Institute, believes the study opens an entirely new door for future therapies.

“Our results suggest that altered metabolism is a significant contributor to Alzheimer’s progression,” Sun stated. He noted that addressing this specific metabolic defect could serve as an essential complement to existing treatments that target traditional Alzheimer’s markers, such as amyloid plaques and tau tangles.

Context: A Ubiquitous Joint Remedy

Glucosamine is usually manufactured from corn or the shells of shellfish. It is deeply embedded in the daily routines of aging adults, primarily used to manage the pain and stiffness of osteoarthritis.

Data from the National Institutes of Health (NIH), cited by the Arthritis Foundation, indicates that roughly 6.5 million American adults regularly use glucosamine or chondroitin products. In fact, estimates show that nearly 20% of middle-aged and older adults in the United States, United Kingdom, and Australia take these supplements.

For years, the supplement has maintained an excellent safety profile. A comprehensive 2025 systemic review evaluating 102 efficacy studies confirmed that glucosamine is generally effective and well-tolerated for joint health, with the vast majority of safety trials reporting no adverse side effects or only mild digestive symptoms like heartburn or nausea. Because it has historical safety data, its sudden statistical link to cognitive decline has caught the medical community by surprise.

Public Health Implications

The scale of supplement use makes these findings a vital public health consideration. The Alzheimer’s Association’s 2026 report estimates that 7.4 million Americans aged 65 and older are currently living with Alzheimer’s dementia. The economic toll is equally staggering, costing the nation $409 billion in 2026 alone, with projections marching toward $1 trillion by 2050.

Standard clinical data shows that 10% to 15% of individuals with mild cognitive impairment naturally transition to full dementia each year. If an over-the-counter supplement increases those odds by a quarter, the collective impact on public health infrastructure and family caregiving could be profound.

“A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse,” Sun noted.

Limitations and Conflicting Evidence

A core tenet of medical journalism is balancing new data against existing science. This study has notable caveats and directly conflicts with some prior research:

• The UK Biobank Contradiction: A massive 2023 cohort study utilizing the UK Biobank database found the opposite effect. Regular glucosamine use in that population was linked to a 16% lower risk of all-cause dementia and a 17% lower risk of Alzheimer’s disease.

• Age Distinctions: The 2023 UK study noted that the protective, positive effects of glucosamine were strongest in participants under the age of 60. This hints that the supplement might behave differently in a younger, healthier metabolic environment versus an older brain.

• No Incident Risk Found in 2024: A separate population-based cohort study published in 2024 tracked habitual glucosamine supplementation and found zero statistical association—positive or negative—with incident dementia risk.

• Lack of Clinical Trials: Electronic health records can be incomplete. Patients may underreport doses, or choose to start and stop supplements without notifying their physicians, making prospective human clinical trials necessary before any official clinical guidelines are altered.

What This Means for Your Daily Health Decisions

Navigating conflicting medical studies can be frustrating for consumers. Based on the current balance of evidence, medical professionals suggest a nuanced approach to daily supplement regimens:

1. For individuals with diagnosed MCI or Dementia: It is highly recommended to sit down with your primary care physician or neurologist to discuss whether the potential risks of glucosamine outweigh its joint benefits.

2. For adults using glucosamine strictly for Osteoarthritis (with no cognitive issues): Because the study demonstrated no negative impact on the group with mild cognitive impairment alone, the supplement remains a viable, widely tolerated tool for managing joint pain.

3. General safety precautions: As always, the Mayo Clinic reminds consumers that those with shellfish allergies must seek out vegan, corn-derived alternatives. Individuals managing diabetes should closely monitor their blood glucose levels, as glucosamine is structurally a carbohydrate and can occasionally influence blood sugar profiles.

Ultimately, this study turns over a fresh stone in dementia research. While it does not provide an absolute mandate to throw away your joint supplements, it highlights an important modifiable pathway. By understanding how sugar attachment influences the brain, scientists may find a way to preserve both joint mobility and cognitive clarity in the future.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.reuters.com/business/healthcare-pharmaceuticals/glucosamine-used-joint-pain-linked-dementia-progression-2026-06-12/